Breaking News

AstraZeneca Unit Acquires AlphaCore Pharma

April 3, 2013

Adds early-stage cardiovascular drug

AstraZeneca’s MedImmune unit has acquired AlphaCore Pharma, a privately held U.S. biotechnology company developing a new type of cholesterol medicine. Financial details were not disclosed.
AlphaCore’s lead drug candidate ACP-501, a genetically engineered liver-derived enzyme called LCAT, completed Phase I trials last year. ACP-501 is being developed to help manage cholesterol to reduce the risk of heart attacks and strokes. It could also play a role in a rare, hereditary disorder called familial LCAT deficiency in which the LCAT enzyme is absent.
"As the science in this area continues to evolve, we are committed to exploring unique pathways that could lead to new combination or standalone therapies for patients living with chronic and acute cardiovascular diseases," said MedImmune head Bahija Jallal.

Related Contract Manufacturing:

blog comments powered by Disqus
  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer

  • Who’s the Right Service Provider for You?

    Who’s the Right Service Provider for You?

    Raymond Peck, VxP Pharma Services||June 2, 2016
    Factors to consider when choosing between using one integrated CDMO or a series of smaller functional service providers